AxoGen NASDAQ:AXGN is reporting this earnings, what to expect.

0
201

AxoGen NASDAQ:AXGN is reporting this earnings, what to expect.

AxoGen is stock market daily expected to report earnings on 04/30/2018 after market close. The report will be for the fiscal Quarter ending Mar 2018. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.11. The reported EPS for the same quarter last year was $-0.11.

()
()

Chart

Overview of AxoGen NASDAQ:AXGN

AxoGen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen’s portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to modulate inflammation. Along with these core surgical products, AxoGen also offers AxoTouch® Two-Point Discriminator and AcroVal® Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries.

AXGN
Name
Change
% Change
Market Cap
% Change from 52 Week Low
% Change from 52 Week High
Shares Outstanding
Volume
Dividend Rate